Healthcare Professionals

CancerTYPE ID News & Reviews

Biotheranostics CancerTYPE ID® aids in patient selection for immunotherapy

September 21, 2020

Biotheranostics announces the publication of a new study evaluating CancerTYPE ID® and its role in identifying subsets of patients with Cancer of Unknown Primary (CUP) that may be eligible for site directed immunotherapy...

Read More

Biotheranostics appoints F. Anthony Greco, M.D. as Medical Advisor for its CancerTYPE ID® molecular assay

July 1, 2019

Biotheranostics, Inc., announces F. Anthony Greco, MD as Medical Advisor for its CancerTYPE ID® test. CancerTYPE ID helps with identification of tumor type and subtype when a diagnosis remains unclear following standard diagnostic evaluation...

Read More

CancerTYPE ID® Prospective Trial Published in ASCO Journal of Precision Oncology

March 19, 2018

Biotheranostics, Inc., reports publication in JCO Precision Oncology of a prospective, multi-institutional, clinical utility study evaluating the impact of CancerTYPE ID on final diagnosis and treatment in patients with an unknown or unclear metastatic cancer diagnosis...

Read More

Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

December 2015

The application of molecularly targeted cancer therapies has rapidly expanded in the past 2 decades. The identification of genetic mutations in tumors has led to a growing list of therapies developed to specifically target those alterations. Indeed, molecularly targeted therapies...

Read More

CancerType ID Indications for Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.